STX209 (Arbaclofen) for autism spectrum disorders

An 8-week open-label study

Craig A. Erickson, Jeremy M. Veenstra-Vanderweele, Raun D. Melmed, James T. McCracken, Lawrence D. Ginsberg, Linmarie Sikich, Lawrence Scahill, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Randall L. Carpenter, Mark F. Bear, Paul P. Wang, Bryan H. King

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder - Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC) - Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.

Original languageEnglish (US)
Pages (from-to)958-964
Number of pages7
JournalJournal of Autism and Developmental Disorders
Volume44
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Checklist
GABA-B Receptor Agonists
Fragile X Syndrome
Lethargy
Autistic Disorder
Synaptic Transmission
Placebos
Outcome Assessment (Health Care)
Safety
Autism Spectrum Disorder

Keywords

  • Arbaclofen
  • Autism spectrum disorder
  • Clinical trial
  • Gamma-aminobutyric acid (GABA)
  • STX209

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., ... King, B. H. (2014). STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study. Journal of Autism and Developmental Disorders, 44(4), 958-964. https://doi.org/10.1007/s10803-013-1963-z

STX209 (Arbaclofen) for autism spectrum disorders : An 8-week open-label study. / Erickson, Craig A.; Veenstra-Vanderweele, Jeremy M.; Melmed, Raun D.; McCracken, James T.; Ginsberg, Lawrence D.; Sikich, Linmarie; Scahill, Lawrence; Cherubini, Maryann; Zarevics, Peter; Walton-Bowen, Karen; Carpenter, Randall L.; Bear, Mark F.; Wang, Paul P.; King, Bryan H.

In: Journal of Autism and Developmental Disorders, Vol. 44, No. 4, 2014, p. 958-964.

Research output: Contribution to journalArticle

Erickson, CA, Veenstra-Vanderweele, JM, Melmed, RD, McCracken, JT, Ginsberg, LD, Sikich, L, Scahill, L, Cherubini, M, Zarevics, P, Walton-Bowen, K, Carpenter, RL, Bear, MF, Wang, PP & King, BH 2014, 'STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study', Journal of Autism and Developmental Disorders, vol. 44, no. 4, pp. 958-964. https://doi.org/10.1007/s10803-013-1963-z
Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L et al. STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study. Journal of Autism and Developmental Disorders. 2014;44(4):958-964. https://doi.org/10.1007/s10803-013-1963-z
Erickson, Craig A. ; Veenstra-Vanderweele, Jeremy M. ; Melmed, Raun D. ; McCracken, James T. ; Ginsberg, Lawrence D. ; Sikich, Linmarie ; Scahill, Lawrence ; Cherubini, Maryann ; Zarevics, Peter ; Walton-Bowen, Karen ; Carpenter, Randall L. ; Bear, Mark F. ; Wang, Paul P. ; King, Bryan H. / STX209 (Arbaclofen) for autism spectrum disorders : An 8-week open-label study. In: Journal of Autism and Developmental Disorders. 2014 ; Vol. 44, No. 4. pp. 958-964.
@article{d8b28a527bce436299454b055c61b792,
title = "STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study",
abstract = "STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder - Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC) - Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.",
keywords = "Arbaclofen, Autism spectrum disorder, Clinical trial, Gamma-aminobutyric acid (GABA), STX209",
author = "Erickson, {Craig A.} and Veenstra-Vanderweele, {Jeremy M.} and Melmed, {Raun D.} and McCracken, {James T.} and Ginsberg, {Lawrence D.} and Linmarie Sikich and Lawrence Scahill and Maryann Cherubini and Peter Zarevics and Karen Walton-Bowen and Carpenter, {Randall L.} and Bear, {Mark F.} and Wang, {Paul P.} and King, {Bryan H.}",
year = "2014",
doi = "10.1007/s10803-013-1963-z",
language = "English (US)",
volume = "44",
pages = "958--964",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - STX209 (Arbaclofen) for autism spectrum disorders

T2 - An 8-week open-label study

AU - Erickson, Craig A.

AU - Veenstra-Vanderweele, Jeremy M.

AU - Melmed, Raun D.

AU - McCracken, James T.

AU - Ginsberg, Lawrence D.

AU - Sikich, Linmarie

AU - Scahill, Lawrence

AU - Cherubini, Maryann

AU - Zarevics, Peter

AU - Walton-Bowen, Karen

AU - Carpenter, Randall L.

AU - Bear, Mark F.

AU - Wang, Paul P.

AU - King, Bryan H.

PY - 2014

Y1 - 2014

N2 - STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder - Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC) - Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.

AB - STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder - Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC) - Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.

KW - Arbaclofen

KW - Autism spectrum disorder

KW - Clinical trial

KW - Gamma-aminobutyric acid (GABA)

KW - STX209

UR - http://www.scopus.com/inward/record.url?scp=84896405056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896405056&partnerID=8YFLogxK

U2 - 10.1007/s10803-013-1963-z

DO - 10.1007/s10803-013-1963-z

M3 - Article

VL - 44

SP - 958

EP - 964

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 4

ER -